Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.

NCT04006262 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Localized Oesogastric Adenocarcimona
MSI and or dMMR

Interventions

DRUG: Nivolumab 10 MG/ML
DRUG: Ipilimumab 200 MG in 40 ML Injection

Sponsor

GERCOR - Multidisciplinary Oncology Cooperative Group

Collaborators

[object Object]